← Back to headlines
AbbVie Gains EU Approval for Atogepant in Acute Migraine Treatment
AbbVie has received EU approval for atogepant, a treatment for acute migraine, expanding its therapeutic offerings in the European market.
2 Jun, 10:54 — 2 Jun, 10:54
Sources
Showing 1 of 1 sources
